Clinical Trial Detail

NCT ID NCT02057133
Title A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Recruitment Active, not recruiting
Gender female
Phase Phase I
Variant Requirements Yes
Sponsors Eli Lilly and Company

Her2-receptor negative breast cancer

Her2-receptor positive breast cancer


Abemaciclib + Loperamide + Pertuzumab + Trastuzumab

Abemaciclib + Fulvestrant + LY3023414

Abemaciclib + Letrozole

Abemaciclib + Exemestane


Abemaciclib + Everolimus + Exemestane

Abemaciclib + Anastrozole

Abemaciclib + Tamoxifen

Abemaciclib + Trastuzumab

Age Groups: adult senior

Additional content available in CKB BOOST